Cognition Therapeutics Releases New Episode of “Conversations” Podcast Recorded at CTAD with Quantitative EEG Experts, Drs Willem de Haan and Philip ScheltensGlobeNewsWire • 11/16/23
Cognition Therapeutics Presents Preclinical Data Identifying Pathways Impacted by Sigma-2 Receptor Modulators in Alzheimer's and Parkinson's DiseasesGlobeNewsWire • 11/15/23
Cognition Therapeutics Completes Enrollment in Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 11/07/23
Cognition Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/02/23
Cognition Therapeutics and Collaborators at Yale and ACTC Announce Oral Late-breaking Presentation on the START Study in Early Alzheimer's Disease at CTADGlobeNewsWire • 10/27/23
Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer's Disease at CTADGlobeNewsWire • 10/24/23
Cognition Therapeutics Presents New Data at CTAD Conference from Advancing Pipeline Across Multiple CNS IndicationsGlobeNewsWire • 10/16/23
Cognition Therapeutics Announces New Conversations Episode on Therapeutic Strategies to Protect the Retina in Dry AMDGlobeNewsWire • 09/07/23
Cognition Therapeutics Announces Participation in Upcoming September ConferencesGlobeNewsWire • 08/30/23
Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business UpdateGlobeNewsWire • 08/08/23
Cognition Therapeutics to Report Second Quarter 2023 Results in Conference Call on Tuesday, August 8, 2023GlobeNewsWire • 08/02/23
Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMDGlobeNewsWire • 07/11/23
Cognition Therapeutics and the Alzheimer's Clinical Trials Consortium Initiate First Clinical Site in the Phase 2 START Study in Early Alzheimer's DiseaseGlobeNewsWire • 07/05/23
Cognition Therapeutics Announces Positive Topline Results for CT1812 Phase 2 SEQUEL Study for Mild-to-Moderate Alzheimer's DiseaseGlobeNewsWire • 06/28/23
Cognition Therapeutics to Host Call and Webcast to Discuss Topline Results from CT1812 Phase 2 SEQUEL Study on June 28, 2023GlobeNewsWire • 06/27/23
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer's Disease ApproachesGlobeNewsWire • 06/20/23
Cognition Therapeutics Continues Investor Engagement in June with Presentations at World Medical Innovation and Longwood Healthcare Leaders ConferencesGlobeNewsWire • 06/02/23
Cognition Therapeutics Latest Episode of “Conversations” Podcast Features Biomarker Experts from Gothenburg University, Emory and Amsterdam UMCGlobeNewsWire • 05/23/23
Cognition Therapeutics Publishes Clinical Evidence that CT1812 Displaces Aβ Oligomers from Binding to Neuronal Synapses in Alzheimer's DiseaseGlobeNewsWire • 05/18/23
Cognition Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 05/04/23
Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial OfficerGlobeNewsWire • 05/01/23
Cognition Therapeutics to Present Analysis Showing Impact of CT1812 on Pathways Implicated in Dry Age-related Macular Degeneration at ARVO 2023GlobeNewsWire • 04/19/23
Cognition Therapeutics Announces New Scientific Publication on Therapeutic Potential of Targeting Sigma-2 Receptor for Age-related Degenerative DiseasesGlobeNewsWire • 04/12/23